Literature DB >> 22079047

Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.

Peter de Bruijn1, Anne-Joy M de Graan, Annemieke Nieuweboer, Ron H J Mathijssen, Mei-Ho Lam, Ronald de Wit, Erik A C Wiemer, Walter J Loos.   

Abstract

A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the quantitative determination of cabazitaxel, a novel tubulin-binding taxane, in 100 μl aliquots of human lithium heparinized plasma with deuterated cabazitaxel as internal standard. The sample extraction and cleaning-up involved a simple liquid-liquid extraction with 20 μl aliquots of 4% ammonium hydroxide, 100 μl aliquots of acetonitrile and 1 ml aliquots of n-butylchloride. Chromatographic separations were achieved on a reversed phase C₁₈ column eluted at a flow-rate of 0.20 ml/min on a gradient of acetonitrile. The overall cycle time of the method was 5 min, with cabazitaxel eluting at 3.0 min. The multiple reaction monitoring transitions were set at 836>555 (m/z), and 842>561 (m/z) for cabazitaxel and the internal standard, respectively. The calibration curves were linear over the range of 1.00-100 ng/ml with the lower limit of quantitation validated at 1.00 ng/ml. The within-run and between-run precisions, also at the level of the LLQ, were within 8.75%, while the accuracy ranged from 88.5 to 94.1%. As dilution of samples prior to extraction resulted in a loss of cabazitaxel of approximately 6.5% per dilution step, a second calibration curve ranging from 40.0 to 4000 ng/ml was validated and was also linear. The within-run and between-run precisions in this range were within 4.99%, while the accuracy ranged from 95.8 to 100.3%. The method was successfully applied to samples derived from a clinical study.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079047     DOI: 10.1016/j.jpba.2011.10.010

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Loss of SLCO1B3 drives taxane resistance in prostate cancer.

Authors:  Ellen S de Morrée; René Böttcher; Robert J van Soest; Ashraf Aghai; Corrina M de Ridder; Alice A Gibson; Ron Hj Mathijssen; Herman Burger; Erik Ac Wiemer; Alex Sparreboom; Ronald de Wit; Wytske M van Weerden
Journal:  Br J Cancer       Date:  2016-08-18       Impact factor: 7.640

2.  A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.

Authors:  Analía Azaro; Jordi Rodón; Jean-Pascal Machiels; Sylvie Rottey; Silvia Damian; Richard Baird; Javier Garcia-Corbacho; Ron H J Mathijssen; Pierre-François Clot; Claudine Wack; Liji Shen; Maja J A de Jonge
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-27       Impact factor: 3.333

3.  Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.

Authors:  A Janssen; C P M Verkleij; A van der Vlist; R H J Mathijssen; H J Bloemendal; R Ter Heine
Journal:  Br J Cancer       Date:  2017-04-11       Impact factor: 7.640

4.  Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.

Authors:  Fabien Calcagno; Thierry Nguyen; Erion Dobi; Cristian Villanueva; Elsa Curtit; Stefano Kim; Philippe Montcuquet; François Kleinclauss; Xavier Pivot; Antoine Thiery-Vuillemin
Journal:  Clin Med Insights Oncol       Date:  2012-12-20

5.  Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.

Authors:  M Laganà; S Grisanti; R Ambrosini; D Cosentini; A Abate; M Zamparini; V D Ferrari; A Gianoncelli; A Turla; L Canu; M Terzolo; G A M Tiberio; S Sigala; A Berruti
Journal:  ESMO Open       Date:  2022-03-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.